Ropivacaine is a local anesthetic used to numb specific areas of the body during surgery, dental procedures, or to relieve pain after certain medical procedures.[2] Naropin is currently approved and in use across 76 indications[4].[1]
Naropin is one of 1015 small molecule programs targeting Childhood Cancer. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Naropin
Avastin
Gemzar
Cymbalta
Lupron
MS Contin
Methylthioninium Chloride
Zinecard
Tricor
Cortef
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 4, 2011
NAROPIN
NDA NDA020533
Sources
Details
Patent Cliff
Nov 28, 2026
Earliest patent expiration — generic entry possible after this date